Publication date: Mar 22, 2025
To examine the effectiveness of exercise interventions to improve long COVID symptoms and the tolerance of exercise interventions among people with long COVID. Systematic review. Medline via EBSCOhost, Embase via OVID and CENTRAL via the Cochrane Library up to 28 February 2023. Inclusion criteria were: (1) participants with long COVID, as defined by study authors; (2) random assignment to either an exercise intervention or a comparison group and (3) a quantitative measure of at least 1 of the 12 core long COVID outcomes. Exclusion criteria were: (1) signs or symptoms not reasonably attributable to prior SARS-CoV-2 infection; (2) pre-exposure or postexposure prophylaxis for COVID-19 or the prevention of long COVID symptoms and (3) interventions where the primary exercise component is breathing or respiratory muscle training. Two reviewers independently extracted data, and studies were narratively synthesised. Eight studies were included. Follow-up periods ranged from 2 to 28 weeks (mean=8. 5 weeks). Sample sizes ranged from 39 to 119 (mean=56). All studies were in adults (mean age=49. 9 years) and both sexes (mean female proportion=53. 9%). Four studies were at low risk of bias, two were unclear and two were high. The evidence suggests that exercise interventions lead to short-term improvements in dyspnoea, fatigue, physical function and the physical domain of quality of life among people with long COVID. Of the five studies that reported adverse events, rates were low and, when reported, mild. Of the seven studies that reported sufficient relevant information, 1 of 252 participants who received exercise discontinued the intervention due to tolerance-related issues. Available evidence suggests that exercise interventions may be beneficial and tolerable among some people with long COVID. However, the evidence base consists of a limited number of studies with small sample sizes and short follow-up periods.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | long COVID |
disease | IDO | intervention |
disease | MESH | SARS-CoV-2 infection |
pathway | REACTOME | SARS-CoV-2 Infection |
disease | IDO | quality |
disease | MESH | infection |
disease | MESH | sequelae |
disease | MESH | breathlessness |
drug | DRUGBANK | Indoleacetic acid |
disease | MESH | chronic illnesses |
disease | IDO | symptom |
drug | DRUGBANK | Trestolone |
disease | IDO | country |
disease | MESH | anxiety |
disease | MESH | functional status |
disease | MESH | depression |